The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vonoprazan: First Global Approval

(2015) Karly P. Garnock-Jones   DRUGS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Systematic Comparison of Molecular Conformations of H+,K+-ATPase Reveals an Important Contribution of the A-M2 Linker for the Luminal Gating

(2014) Kazuhiro Abe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers

(2014) Hua-Jun Luo et al.   PLoS One

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease

(2013) John Dent et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers

(2012) Haruyuki Nishida et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

(2012) Yasuyoshi Arikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

(2010) Hyung-Keun Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Acid peptic diseases: pharmacological approach to treatment

(2009) Alex Mejia et al.   Expert Review of Clinical Pharmacology

The gastric HK-ATPase: structure, function, and inhibition

(2008) Jai Moo Shin et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY